Drug Profile
Research programme: small molecule therapeutics - VistaGen
Alternative Names: Drug rescue variants - VistaGenLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator VistaGen Therapeutics
- Developer Synterys; VistaGen Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in USA
- 23 Apr 2014 VistaGen licenses patents entitled Mesoderm and Definitive Endoderm Cell Populations from Icahn School of Medicine
- 14 Feb 2012 VistaGen has identified its initial top ten drug rescue candidates